Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?

Nuvectis Pharma (NVCT) has a consensus price target implying 61.5% upside, though the article notes such targets are often of limited predictive value. It flags an upward trend in earnings estimate revisions as the more relevant near-term catalyst that could support the stock.

Analysis

Nuvectis Pharma (NVCT) has a consensus price target implying 61.5% upside, though the article notes such targets are often of limited predictive value. It flags an upward trend in earnings estimate revisions as the more relevant near-term catalyst that could support the stock.